Immunoglobulin light chain amyloidosis (Q38172295)

30 August 2017

Immunoglobulin light chain amyloidosis (English)

1 reference

30 August 2017

1

1 reference

30 August 2017

5

Morie A Gertz

1 reference

30 August 2017

Raymond L Comenzo

2

1 reference

PubMed ID

24350907

30 August 2017

David C Seldin

series ordinal

3

1 reference

PubMed ID

24350907

30 August 2017

Ashutosh Wechalekar

series ordinal

4

1 reference

30 August 2017

18 December 2013

1 reference

Expert Review of Hematology

30 August 2017

1 reference

30 August 2017

7

1 reference

30 August 2017

143-156

1 reference

30 August 2017

1

1 reference

Molecular mechanisms of amyloidosis

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Protein misfolding, functional amyloid, and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Systemic light chain amyloidosis: an update for treating physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Introducing the new editor of amyloid: the journal of protein folding disorders, Per Westermark, M.D., Ph.D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

The value of electron microscopy in the diagnosis and clinical management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

21 January 2018

How I treat amyloidosis

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Preclinical development of siRNA therapeutics for AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Antibody-mediated resolution of light chain-associated amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Left ventricular device implantation for advanced cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Transplantation for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Light and electron microscopy immunohistochemical characterization of amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.858594

10.1586/17474086.2014.858594

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24350907